CopyMark Law Group
4.9/5
Drawing for RENMAB

USPTO serial 88553807

RENMAB

Reviewed by CopyMark Law Group

Reg. 8096103Status 700Registered
Filing date
Status date
Registration date
Jan 6, 2026
Examiner
CROWLEY,SEAN MICHAEL
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with RENMAB?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

CYNTHIA JOHNSON WALDEN

CYNTHIA JOHNSON WALDEN Fish & Richardson P.C.PO BOX 1022MINNEAPOLIS, MN 55440-1022United States

Goods and services

ClassDescriptionStatusFirst use
005Medical immunoassay reagent derived from experimental animals; medical biological preparations for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; drugs for treating cancer, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; medicines for human purposes, namely, for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; biochemical drugs for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; immunologic stimulants for medical use for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; bulk drugs for the treatment of diseases, namely, Active Biopharmaceutical Ingredients derived from experimental animals; medical diagnostic preparation, namely, antibodies and proteins for biopharmaceuticals derived from experimental animalsACTIVEJun 1, 2020

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 6, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 6, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 18, 2025SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Dec 18, 2025CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Nov 14, 2025SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Nov 13, 2025IUAFUSE AMENDMENT FILED—
Nov 13, 2025EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Oct 27, 2025DPCCDIVISIONAL PROCESSING COMPLETE—
Oct 23, 2025AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Oct 2, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 1, 2025EX1GSOU EXTENSION 1 GRANTED—
Oct 1, 2025AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
May 19, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 18, 2025DRRRDIVISIONAL REQUEST RECEIVED—
May 18, 2025EXT1SOU EXTENSION 1 FILED—
May 18, 2025ERTDTEAS REQUEST TO DIVIDE RECEIVED—
May 13, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 1, 2025EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Nov 19, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 21, 2024TMBNTTAB RELEASE CASE TO TRADEMARKS—
Oct 21, 2024OP.TOPPOSITION TERMINATED NO. 999999—
Oct 21, 2024OP.DOPPOSITION DISMISSED NO. 999999—
Feb 14, 2022OP.IOPPOSITION INSTITUTED NO. 999999—
Sep 15, 2021ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Aug 17, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 17, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 28, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 9, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 9, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 9, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 6, 2021ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Feb 17, 2021ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jan 5, 2021GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Jan 5, 2021GNSIINQUIRY TO SUSPENSION E-MAILED—
Jan 5, 2021CNSISUSPENSION INQUIRY WRITTEN—
Dec 2, 2020RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
May 29, 2020GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
May 29, 2020GNSLLETTER OF SUSPENSION E-MAILED—
May 29, 2020CNSLSUSPENSION LETTER WRITTEN—
May 12, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 12, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 8, 2020ALIEASSIGNED TO LIE—
May 5, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 5, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 5, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 5, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 28, 2019DOCKASSIGNED TO EXAMINER—
Aug 14, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 3, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance